CAS Key Laboratory of Soft Matter Chemistry, Department of Chemistry, University of Science and Technology of China, 96 Jinzhai Road, Hefei, Anhui 230026 (China) http://lianglab.ustc.edu.cn.
School of Life Sciences, University of Science and Technology of China, Hefei, Anhui 230027 (China).
Angew Chem Int Ed Engl. 2015 Aug 10;54(33):9700-4. doi: 10.1002/anie.201504329. Epub 2015 Jun 26.
Multidrug resistance (MDR) remains the biggest challenge in treating cancers. Herein we propose the intracellular self-assembly of nanodrugs as a new strategy for overcoming MDR. By employing a biocompatible condensation reaction, we rationally designed a taxol derivative Ac-Arg-Val-Arg-Arg-Cys(StBu)-Lys(taxol)-2-cyanobenzothiazole (CBT-Taxol) which could be subjected to furin-controlled condensation and self-assembly of taxol nanoparticles (Taxol-NPs). In vitro and in vivo studies indicated that, compared with taxol, CBT-Taxol showed a 4.5-fold or 1.5-fold increase in anti-MDR effects, respectively, on taxol-resistant HCT 116 cancer cells or tumors without being toxic to the cells or the mice. Our results demonstrate that structuring protease-susceptible agents and assembling them intracellularly into nanodrugs could be a new optimal strategy for overcoming MDR.
多药耐药(MDR)仍然是癌症治疗的最大挑战。在此,我们提出了纳米药物的细胞内自组装作为克服 MDR 的一种新策略。通过采用生物相容性的缩合反应,我们合理设计了一种紫杉醇衍生物 Ac-Arg-Val-Arg-Arg-Cys(StBu)-Lys(紫杉醇)-2-氰基苯并噻唑(CBT-紫杉醇),它可以受到弗林蛋白酶控制的缩合和紫杉醇纳米颗粒(Taxol-NPs)的自组装。体外和体内研究表明,与紫杉醇相比,CBT-紫杉醇对紫杉醇耐药的 HCT116 癌细胞或肿瘤的抗 MDR 作用分别增加了 4.5 倍或 1.5 倍,而对细胞或小鼠没有毒性。我们的结果表明,将蛋白酶敏感剂构建并在细胞内组装成纳米药物可能是克服 MDR 的一种新的最佳策略。